Antipsychotic Drug Market

The global antipsychotic drug market is predicted to reach USD 18.5 billion in 2020.

The compound annual growth rate is expected to be 4.5% over the forecast period of 2019-2025 according to Market Research Future.

Factors like poor efficacy and efficiency of anti-psychotic drugs, different side effects related to taking the drugs like drowsiness, vomiting, high addiction rate, and social stigma, insomnia, poor drug development pipeline and stringent regulatory framework are likely to curb the growth of antipsychotic drugs market over the predicted years.

North American is the largest regional antipsychotic drug market and holds the potential of being a dominant market because of heavy investment in the R&D related to medicines and drugs.

Furthermore, technological advancements and availability of advanced medical facilities, in this region account for it having a larger regional antipsychotic drugs market size than South America.

USA and Canada produce the largest market revenue in this region.

Many important key companies are based in the USA.

Two key factors drive the market growth in this region.

These are the excellent reimbursements in the USA along with the rapid uptake of new drug molecules.

The second-largest regional antipsychotic drugs market is found in Europe.

Additional factors that contribute towards this large market size include a high density of population with other reasons being like those in North America.

Some of the larger country-specific markets in Europe are Germany, France, Italy, Spain, and the UK.

An inspection of the remaining countries in Europe featured in this report speculate the huge contribution to market revenue from some other countries in this region.

The Asia Pacific region may become the fastest growing regional market due to the high density of population, improving healthcare facilities, and government efforts to improve healthcare, particularly in China and India.

Other key country-specific markets in this region are Japan and South Korea.

Due to poor medical facilities and lack of skilled professionals, the Middle East and African region holds the lowest global antipsychotic drugs market share.





CONTACT US

Email Us Follow on Twitter

Val Schabinsky

Founder and Chairman

37 President Road Kellyville
NSW Australia 2155

Tel: +61298361669
Mob: +61404876694
Fax: +61298361669
Web: www.internationalclinicaltrials.com